294 related articles for article (PubMed ID: 23728939)
1. Preclinical analysis of resistance and cross-resistance to low-dose metronomic chemotherapy.
Chow A; Wong A; Francia G; Man S; Kerbel RS; Emmenegger U
Invest New Drugs; 2014 Feb; 32(1):47-59. PubMed ID: 23728939
[TBL] [Abstract][Full Text] [Related]
2. Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer.
Hashimoto K; Man S; Xu P; Cruz-Munoz W; Tang T; Kumar R; Kerbel RS
Mol Cancer Ther; 2010 Apr; 9(4):996-1006. PubMed ID: 20371722
[TBL] [Abstract][Full Text] [Related]
3. Analysis of acquired resistance to metronomic oral topotecan chemotherapy plus pazopanib after prolonged preclinical potent responsiveness in advanced ovarian cancer.
Cruz-Muñoz W; Di Desidero T; Man S; Xu P; Jaramillo ML; Hashimoto K; Collins C; Banville M; O'Connor-McCourt MD; Kerbel RS
Angiogenesis; 2014 Jul; 17(3):661-73. PubMed ID: 24569856
[TBL] [Abstract][Full Text] [Related]
4. Tumors that acquire resistance to low-dose metronomic cyclophosphamide retain sensitivity to maximum tolerated dose cyclophosphamide.
Emmenegger U; Francia G; Chow A; Shaked Y; Kouri A; Man S; Kerbel RS
Neoplasia; 2011 Jan; 13(1):40-8. PubMed ID: 21245939
[TBL] [Abstract][Full Text] [Related]
5. Low-dose metronomic combined with intermittent bolus-dose cyclophosphamide is an effective long-term chemotherapy treatment strategy.
Shaked Y; Emmenegger U; Francia G; Chen L; Lee CR; Man S; Paraghamian A; Ben-David Y; Kerbel RS
Cancer Res; 2005 Aug; 65(16):7045-51. PubMed ID: 16103050
[TBL] [Abstract][Full Text] [Related]
6. Enhanced antitumor activity of low-dose continuous administration schedules of topotecan in prostate cancer.
Aljuffali IA; Mock JN; Costyn LJ; Nguyen H; Nagy T; Cummings BS; Arnold RD
Cancer Biol Ther; 2011 Sep; 12(5):407-20. PubMed ID: 21709443
[TBL] [Abstract][Full Text] [Related]
7. Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water.
Man S; Bocci G; Francia G; Green SK; Jothy S; Hanahan D; Bohlen P; Hicklin DJ; Bergers G; Kerbel RS
Cancer Res; 2002 May; 62(10):2731-5. PubMed ID: 12019144
[TBL] [Abstract][Full Text] [Related]
8. Docetaxel plus oral metronomic cyclophosphamide: a phase II study with pharmacodynamic and pharmacogenetic analyses in castration-resistant prostate cancer patients.
Derosa L; Galli L; Orlandi P; Fioravanti A; Di Desidero T; Fontana A; Antonuzzo A; Biasco E; Farnesi A; Marconcini R; Francia G; Danesi R; Falcone A; Bocci G
Cancer; 2014 Dec; 120(24):3923-31. PubMed ID: 25111199
[TBL] [Abstract][Full Text] [Related]
9. Clinical outcome of patients with docetaxel-resistant hormone-refractory prostate cancer treated with second-line cyclophosphamide-based metronomic chemotherapy.
Nelius T; Klatte T; de Riese W; Haynes A; Filleur S
Med Oncol; 2010 Jun; 27(2):363-7. PubMed ID: 19365737
[TBL] [Abstract][Full Text] [Related]
10. Metronomic oral cyclophosphamide chemotherapy possibly contributes to stabilization of disease in patients with metastatic castration-resistant prostate cancer: a prospective analysis of consecutive cases.
Yashi M; Nishihara D; Mizuno T; Yuki H; Masuda A; Kambara T; Betsunoh H; Abe H; Fukabori Y; Muraishi O; Kamai T
Clin Genitourin Cancer; 2014 Oct; 12(5):e197-203. PubMed ID: 24674784
[TBL] [Abstract][Full Text] [Related]
11. Metronomic oral topotecan with pazopanib is an active antiangiogenic regimen in mouse models of aggressive pediatric solid tumor.
Kumar S; Mokhtari RB; Sheikh R; Wu B; Zhang L; Xu P; Man S; Oliveira ID; Yeger H; Kerbel RS; Baruchel S
Clin Cancer Res; 2011 Sep; 17(17):5656-67. PubMed ID: 21788355
[TBL] [Abstract][Full Text] [Related]
12. The potential clinical promise of 'multimodality' metronomic chemotherapy revealed by preclinical studies of metastatic disease.
Kerbel RS; Shaked Y
Cancer Lett; 2017 Aug; 400():293-304. PubMed ID: 28202353
[TBL] [Abstract][Full Text] [Related]
13. Functional and pharmacodynamic evaluation of metronomic cyclophosphamide and docetaxel regimen in castration-resistant prostate cancer.
Cardillo I; Spugnini EP; Galluzzo P; Contestabile M; Dell'Anna ML; Picardo M; Crispi S; Calogero RA; Piccolo MT; Arigoni M; Cantarella D; Boccellino M; Quagliuolo L; Ferretti G; Carlini P; Felici A; Boccardo F; Cognetti F; Baldi A
Future Oncol; 2013 Sep; 9(9):1375-88. PubMed ID: 23980684
[TBL] [Abstract][Full Text] [Related]
14. [Efficacy of standard docetaxel and metronomic cyclophosphamide chemotherapy in patients with hormone-resistant prostate cancer: comparative analysis].
Vorob'ev NA; Nosov AK; Vorob'ev AV; Moiseenko BM
Vopr Onkol; 2011; 57(6):753-8. PubMed ID: 22416393
[TBL] [Abstract][Full Text] [Related]
15. Everolimus (RAD001) sensitizes prostate cancer cells to docetaxel by down-regulation of HIF-1α and sphingosine kinase 1.
Alshaker H; Wang Q; Kawano Y; Arafat T; Böhler T; Winkler M; Cooper C; Pchejetski D
Oncotarget; 2016 Dec; 7(49):80943-80956. PubMed ID: 27821815
[TBL] [Abstract][Full Text] [Related]
16. Metronomic low-dose chemotherapy boosts CD95-dependent antiangiogenic effect of the thrombospondin peptide ABT-510: a complementation antiangiogenic strategy.
Yap R; Veliceasa D; Emmenegger U; Kerbel RS; McKay LM; Henkin J; Volpert OV
Clin Cancer Res; 2005 Sep; 11(18):6678-85. PubMed ID: 16166447
[TBL] [Abstract][Full Text] [Related]
17. Low-dose metronomic cyclophosphamide combined with vascular disrupting therapy induces potent antitumor activity in preclinical human tumor xenograft models.
Daenen LG; Shaked Y; Man S; Xu P; Voest EE; Hoffman RM; Chaplin DJ; Kerbel RS
Mol Cancer Ther; 2009 Oct; 8(10):2872-81. PubMed ID: 19825805
[TBL] [Abstract][Full Text] [Related]
18. Postsurgical adjuvant or metastatic renal cell carcinoma therapy models reveal potent antitumor activity of metronomic oral topotecan with pazopanib.
Jedeszko C; Paez-Ribes M; Di Desidero T; Man S; Lee CR; Xu P; Bjarnason GA; Bocci G; Kerbel RS
Sci Transl Med; 2015 Apr; 7(282):282ra50. PubMed ID: 25855496
[TBL] [Abstract][Full Text] [Related]
19. Salvage therapy with oral metronomic cyclophosphamide and methotrexate for castration-refractory metastatic adenocarcinoma of the prostate resistant to docetaxel.
Gebbia V; Serretta V; Borsellino N; Valerio MR;
Urology; 2011 Nov; 78(5):1125-30. PubMed ID: 22054386
[TBL] [Abstract][Full Text] [Related]
20. Low-dose metronomic daily cyclophosphamide and weekly tirapazamine: a well-tolerated combination regimen with enhanced efficacy that exploits tumor hypoxia.
Emmenegger U; Morton GC; Francia G; Shaked Y; Franco M; Weinerman A; Man S; Kerbel RS
Cancer Res; 2006 Feb; 66(3):1664-74. PubMed ID: 16452226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]